Canada Pension Plan Investment Board Boosts Position in Pfizer Inc. (NYSE:PFE)

Canada Pension Plan Investment Board increased its holdings in shares of Pfizer Inc. (NYSE:PFE) by 125.2% in the 1st quarter, HoldingsChannel reports. The firm owned 13,765,773 shares of the biopharmaceutical company’s stock after acquiring an additional 7,654,145 shares during the quarter. Canada Pension Plan Investment Board’s holdings in Pfizer were worth $498,734,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also bought and sold shares of the business. North American Management Corp grew its holdings in Pfizer by 4.0% during the first quarter. North American Management Corp now owns 186,886 shares of the biopharmaceutical company’s stock worth $6,771,000 after acquiring an additional 7,122 shares during the period. Jones Financial Companies Lllp boosted its holdings in Pfizer by 2.0% during the first quarter. Jones Financial Companies Lllp now owns 358,298 shares of the biopharmaceutical company’s stock worth $12,981,000 after buying an additional 7,005 shares in the last quarter. Cito Capital Group LLC grew its position in Pfizer by 59.6% during the first quarter. Cito Capital Group LLC now owns 38,831 shares of the biopharmaceutical company’s stock valued at $1,407,000 after buying an additional 14,500 shares during the period. Guggenheim Capital LLC increased its holdings in Pfizer by 2.8% in the first quarter. Guggenheim Capital LLC now owns 1,461,508 shares of the biopharmaceutical company’s stock valued at $52,950,000 after buying an additional 40,497 shares in the last quarter. Finally, Kanawha Capital Management LLC boosted its stake in shares of Pfizer by 2.5% during the 1st quarter. Kanawha Capital Management LLC now owns 233,336 shares of the biopharmaceutical company’s stock worth $8,454,000 after acquiring an additional 5,682 shares in the last quarter. 64.10% of the stock is currently owned by institutional investors.

PFE has been the subject of a number of recent analyst reports. JPMorgan Chase & Co. set a $40.00 price objective on Pfizer and gave the company a “neutral” rating in a research report on Monday, May 24th. SVB Leerink boosted their target price on shares of Pfizer from $39.00 to $43.00 and gave the stock a “market perform” rating in a research note on Wednesday, May 5th. Morgan Stanley boosted their price objective on Pfizer from $38.00 to $42.00 and gave the stock an “equal weight” rating in a research note on Monday, May 10th. Royal Bank of Canada lifted their target price on shares of Pfizer from $43.00 to $44.00 and gave the stock a “sector perform” rating in a research note on Thursday, June 17th. Finally, Mizuho reiterated a “neutral” rating and issued a $42.00 target price on shares of Pfizer in a research report on Wednesday, May 12th. Twelve equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of $41.36.

In other Pfizer news, SVP Jennifer B. Damico sold 2,500 shares of the business’s stock in a transaction dated Wednesday, May 5th. The shares were sold at an average price of $40.82, for a total transaction of $102,050.00. Following the sale, the senior vice president now directly owns 13,748 shares in the company, valued at $561,193.36. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.05% of the stock is owned by corporate insiders.

Pfizer stock traded up $0.28 during trading on Thursday, hitting $41.30. The company had a trading volume of 597,746 shares, compared to its average volume of 20,340,868. Pfizer Inc. has a 1-year low of $33.36 and a 1-year high of $43.08. The company has a current ratio of 1.48, a quick ratio of 1.16 and a debt-to-equity ratio of 0.51. The company has a 50 day simple moving average of $39.54. The stock has a market cap of $231.18 billion, a PE ratio of 21.07, a price-to-earnings-growth ratio of 1.46 and a beta of 0.74.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, May 4th. The biopharmaceutical company reported $0.93 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.78 by $0.15. The firm had revenue of $14.58 billion during the quarter, compared to the consensus estimate of $13.41 billion. Pfizer had a net margin of 22.09% and a return on equity of 24.55%. The firm’s revenue for the quarter was up 44.6% on a year-over-year basis. During the same quarter last year, the firm earned $0.80 EPS. On average, equities analysts anticipate that Pfizer Inc. will post 3.71 earnings per share for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 7th. Shareholders of record on Friday, July 30th will be paid a dividend of $0.39 per share. The ex-dividend date of this dividend is Thursday, July 29th. This represents a $1.56 dividend on an annualized basis and a yield of 3.78%. Pfizer’s dividend payout ratio (DPR) is presently 70.27%.

Pfizer Company Profile

Pfizer Inc engages in the discovery, development, and manufacture of healthcare products specializes in medicines, vaccine, and consumer healthcare. It operates through the Pfizer Innovative Health (IH) and Pfizer Essential Health (EH) segments. The IH segment focuses on the development and commercializing medicines and vaccines for internal medicine, oncology, inflammation and immunology, rate disease, and consumer healthcare.

Read More: Understanding and Trading Breakout Stocks

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.